Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

CONCLUSIONS: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy. (Funded by Janssen Research and Development; POLLUX number, NCT02076009.)

 N Engl J Med

click me